We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Although adaptive seamless design (ASD) in clinical trials offers many benefits, “there is no free lunch,” said Sue-Jane Wang, associate director at the FDA’s Office of Biostatistics. Read More
Adaptive clinical trials make it possible for sponsors to enroll smaller numbers of patients, put a quick stop to treatment approaches that aren’t working and save time and money overall, say experts.
Clinical trial supply staffs are significantly larger in Phase III than in Phase II studies for both in-house and outsourced teams, according to a new study based on a survey of almost 40 pharmaceutical, biotech and medical device firms, as well as contract research organizations.
The NIH announced Oct. 3 that it will award almost $700 million in research grants to 12 academic health centers between Oct. 1, 2006, and June 30, 2011, about $100 million of that in the nine-month period ending June 30, 2007.